Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment

MT Newswires Live11-06

Sanofi (SNY) said Wednesday that the European Medicines Agency has approved its drug Dupixent to treat eosinophilic esophagitis in children from one year of age.

Approval for the drug, also called dupilumab and jointly developed by Regeneron Pharmaceuticals (REGN), covers children ages one to 11 years weighing at least 15 kilograms and unable to use conventional medicinal therapies, the company said.

The approval makes dupilumab the first and only medicine to treat children with such conditions, the company said.

It followed a phase 3 study in which 68% of patients experienced disease remission compared to 3% in a control group.

Eosinophilic esophagitis is a chronic, progressive disease that potentially damages the esophagus and impairs its function.

Price: 54.84, Change: +0.48, Percent Change: +0.88

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481621000?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 17:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481621000","market":"us","top_or_hot":-1,"title":"Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) said Wednesday that the European Medicines Agency has approved its drug Dupixent to treat eosinophilic esophagitis in children from one year of age.</p><p>Approval for the drug, also called dupilumab and jointly developed by Regeneron Pharmaceuticals (REGN), covers children ages one to 11 years weighing at least 15 kilograms and unable to use conventional medicinal therapies, the company said.</p><p>The approval makes dupilumab the first and only medicine to treat children with such conditions, the company said.</p><p>It followed a phase 3 study in which 68% of patients experienced disease remission compared to 3% in a control group.</p><p>Eosinophilic esophagitis is a chronic, progressive disease that potentially damages the esophagus and impairs its function.</p><p>Price: 54.84, Change: +0.48, Percent Change: +0.88</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 17:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofi (SNY) said Wednesday that the European Medicines Agency has approved its drug Dupixent to treat eosinophilic esophagitis in children from one year of age.Approval for the drug, also called ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2106854487.HKD","symbol_name":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481621000","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481621000","pubTimestamp":1730884385,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sanofi  said Wednesday that the European Medicines Agency has approved its drug Dupixent to treat eosinophilic esophagitis in children from one year of age.Approval for the drug, also called dupilumab and jointly developed by Regeneron Pharmaceuticals , covers children ages one to 11 years weighing at least 15 kilograms and unable to use conventional medicinal therapies, the company said.The approval makes dupilumab the first and only medicine to treat children with such conditions, the company said.It followed a phase 3 study in which 68% of patients experienced disease remission compared to 3% in a control group.Eosinophilic esophagitis is a chronic, progressive disease that potentially damages the esophagus and impairs its function.Price: 54.84, Change: +0.48, Percent Change: +0.88","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4007":"制药","LU0058720904.USD":"联博国际健康护理基金A","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4588":"碎股","LU0882574055.USD":"富达全球健康医疗A ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","SNY":"赛诺菲安万特","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","REGN":"再生元制药公司","SNYNF":"Sanofi","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元"},"translate_title":"赛诺菲、再生元获得欧洲儿科咽喉疾病治疗批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1,"SNY":0.9,"REGN":0.9},"content_text":"Sanofi (SNY) said Wednesday that the European Medicines Agency has approved its drug Dupixent to treat eosinophilic esophagitis in children from one year of age.Approval for the drug, also called dupilumab and jointly developed by Regeneron Pharmaceuticals (REGN), covers children ages one to 11 years weighing at least 15 kilograms and unable to use conventional medicinal therapies, the company said.The approval makes dupilumab the first and only medicine to treat children with such conditions, the company said.It followed a phase 3 study in which 68% of patients experienced disease remission compared to 3% in a control group.Eosinophilic esophagitis is a chronic, progressive disease that potentially damages the esophagus and impairs its function.Price: 54.84, Change: +0.48, Percent Change: +0.88","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481621000"}